Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
复制标题
DOI：
--
复制
发表时间：
2013-12
影响因子：
1.4
通讯作者：
K. Alagiakrishnan;S. Sankaralingam;M. Ghosh;Laurie Mereu;P. Senior
中科院分区：
文献类型：
--
作者：
K. Alagiakrishnan;S. Sankaralingam;M. Ghosh;Laurie Mereu;P. Senior
糖尿病(DM)和痴呆症的发病率都随着年龄的增长而增加，糖尿病患者痴呆症的发病率更高。流行病学和病理学数据表明，糖尿病会导致轻度认知障碍(MCI)和痴呆。糖尿病似乎是MCI和阿尔茨海默病(AD)的独立危险因素，并与认知能力下降更快有关。最近的证据表明，胰岛素影响中枢神经系统功能，并能调节认知功能。脑内胰岛素信号转导受损和胰岛素抵抗在AD的发病机制中起重要作用。人体研究表明，一些口服抗糖尿病药物可以改善MCI和AD患者的认知。鼻腔注射胰岛素也被证明可以改善MCI和AD患者的记忆和认知能力。虽然目前尚不清楚糖尿病的管理是否会减少MCI和AD的发生率，但越来越多的证据表明，糖尿病治疗可能会改善认知功能。
The incidence of both diabetes mellitus (DM) and dementia increases with aging and the incidence of dementia are higher in people with diabetes. Epidemiological and pathological data suggest that DM contributes to mild cognitive impairment (MCI) and dementia. DM seems to be an independent risk factor for MCI and Alzheimer's disease (AD) and is associated with more rapid cognitive decline. Recent evidence points out that insulin affects central nervous system functions, and can modulate cognitive functions. Impaired insulin signaling and insulin resistance in brain have been found to play an important role in the pathogenesis of AD. Human studies have shown that some oral antidiabetic medications can improve cognition in patients with MCI and AD. Intranasal insulin has also been shown to improve memory and cognitive abilities in MCI and AD patients. While it remains unclear whether management of diabetes will reduce the incidence of MCI and AD, emerging evidence suggests that diabetes therapies may improve cognitive function.